ResMed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Sma ...

As Philips reaches a consent decree agreement with the FDA that will temporarily suspend its sales of sleep therapy devices in the U.S., competitor ResMed, meanwhile, is ramping up its product ...

Please provide your email address to receive an email when new articles are posted on . ResMed CPAP masks that contain magnets are being recalled due to possible magnetic interference with medical ...

The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea. The NightOwl testing device, about the size of a quarter, is worn on the user ...

Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

San Diego, California-based ResMed has received FDA 510(k) clearance for its small, portable continuous positive airway pressure (CPAP) device, the AirMini. The announcement was made during the JP ...

There is a risk of serious injury or death related to more than 20 million CPAP masks made by ResMed, the FDA said Jan. 11. The continuous positive airway pressure masks, branded as AirFit and ...

ResMed (NYSE:RMD) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ...

The U.S. Food and Drug Administration (FDA) on Thursday classified a product recall initiated by ResMed (NYSE:RMD) for its respiratory care devices, AirFit and AirTouch masks, as a Class I recall, the ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...